Topic: Infectious Diseases
Date: 09/17/2021
In this episode, Dr. Christopher Rentsch, of the London School of Hygiene and Tropical Medicine and Yale University, talks about a large-scale evaluation of the effectiveness of prophylactic anticoagulant therapy for the treatment of COVID-19.
Since the recording of this podcast, the largest trial to date, ACTIV-4, has found that initiating therapeutic anticoagulation compared to prophylactic anticoagulation provided additional benefit among patients hospitalized with COVID-19. Both Dr. Rentsch’s study and the ACTIV-4 study found benefit in noncritically ill patients yet not in critically ill patients.
Listen (17:35), Transcript
